store under nitrogen
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Lenvatinib mesylate (E7080 (mesylate)) is an oral and multi-targeted inhibitor of VEGFR1-3, FGFR1-4, PDGFR, KIT, and RET, with potent antitumor activities.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
10 mg | In stock | $ 34.00 | |
25 mg | In stock | $ 55.00 | |
50 mg | In stock | $ 80.00 | |
100 mg | In stock | $ 113.00 | |
200 mg | In stock | $ 168.00 | |
500 mg | In stock | $ 283.00 |
Description | Lenvatinib mesylate (E7080 (mesylate)) is an oral and multi-targeted inhibitor of VEGFR1-3, FGFR1-4, PDGFR, KIT, and RET, with potent antitumor activities. |
Targets&IC50 | c-Kit:100 nM, PDGFRβ:39 nM, PDGFRα:51 nM, FGFR1:46 nM, VEGFR1:22 nM, VEGFR3:5.2 nM, VEGFR2:4 nM |
In vitro | Lenvatinib is a small-molecule tyrosine kinase inhibitor that inhibits vascular endothelial growth factor receptor (VEGFR1-3), fibroblast growth factor receptor (FGFR1-4), platelet-derived growth factor receptor α (PDGFRα), stem cell factor receptor (KIT), and rearranged during transfection (RET).?These receptors are important for tumor angiogenesis, and lenvatinib inhibits tumor angiogenesis by inhibiting function of these receptors[1]. |
Synonyms | E7080 (mesylate) |
Molecular Weight | 522.96 |
Formula | C22H23ClN4O7S |
CAS No. | 857890-39-2 |
store under nitrogen
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 8 mg/mL (15.2 mM), Sonication is recommended.
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Lenvatinib mesylate 857890-39-2 Angiogenesis Apoptosis Tyrosine Kinase/Adaptors VEGFR FGFR PDGFR c-Kit c-RET Inhibitor E-7080 inhibit E7080 (mesylate) RET Vascular endothelial growth factor receptor Fibroblast growth factor receptor CD117 SCFR Lenvatinib Mesylate E7080 E 7080 Platelet-derived growth factor receptor Lenvatinib inhibitor